

Albumin-bound paclitaxel in solid tumors: clinical deve

Drug Design, Development and Therapy
9, 3767

DOI: 10.2147/dddt.s88023

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis. <i>Molecules</i> , 2016, 21, 1468.	1.7	44
3	Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics. <i>Bioconjugate Chemistry</i> , 2016, 27, 2239-2247.	1.8	51
4	Polymeric micelle nanocarriers in cancer research. <i>Frontiers of Chemical Science and Engineering</i> , 2016, 10, 348-359.	2.3	65
5	Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue. <i>Journal of Controlled Release</i> , 2016, 238, 139-148.	4.8	46
6	Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. <i>Interface Focus</i> , 2016, 6, 20160054.	1.5	13
7	Nanomedicines for renal disease: current status and future applications. <i>Nature Reviews Nephrology</i> , 2016, 12, 738-753.	4.1	179
8	Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy. <i>Anti-Cancer Drugs</i> , 2016, 27, 580-584.	0.7	11
9	EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 589-600.	1.7	51
10	Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. <i>Science Translational Medicine</i> , 2016, 8, 325ra17.	5.8	171
11	Microtubule-stabilizing agents: New drug discovery and cancer therapy. , 2016, 162, 134-143.		63
12	Clinical advances of nanocarrier-based cancer therapy and diagnostics. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 75-92.	2.4	67
13	Paclitaxel-loaded hollow-poly(4-vinylpyridine) nanoparticles enhance drug chemotherapeutic efficacy in lung and breast cancer cell lines. <i>Nano Research</i> , 2017, 10, 856-875.	5.8	22
14	Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 7424-7435.	4.0	57
15	Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 182-190.	1.6	126
16	A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4517-4532.	2.9	83
17	High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation. <i>Pharmaceutical Research</i> , 2017, 34, 1180-1186.	1.7	20
18	Cell line studies and analytical measurements of three paclitaxel complex variations. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2793-2799.	1.0	6
19	Use of Nanomedicine in the Diagnosis of Gastric Cancer. , 2017, , 179-188.		0

#	ARTICLE	IF	CITATIONS
20	Nanomedicine for prostate cancer using nanoemulsion: A review. <i>Journal of Controlled Release</i> , 2017, 260, 111-123.	4.8	38
21	Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro. <i>Scientific Reports</i> , 2017, 7, 13506.	1.6	31
22	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. <i>Clinical Cancer Research</i> , 2017, 23, 1564-1574.	3.2	32
23	Nanomedicine Strategies to Target Tumor-Associated Macrophages. <i>International Journal of Molecular Sciences</i> , 2017, 18, 979.	1.8	79
24	An Update On Natural Compounds and Their Modern Formulations for the Management of Malignant Melanoma. , 2017, , .		1
25	Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 659-668.	2.0	34
26	Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. <i>ACS Nano</i> , 2018, 12, 2106-2121.	7.3	117
27	Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1301-1313.	1.7	21
28	Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells. <i>DNA Repair</i> , 2018, 63, 1-9.	1.3	35
29	Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1205-1217.	1.2	12
30	Precise nanomedicine for intelligent therapy of cancer. <i>Science China Chemistry</i> , 2018, 61, 1503-1552.	4.2	336
31	Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway. <i>Oncology Letters</i> , 2018, 16, 5006-5012.	0.8	32
32	Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2353-2364.	1.9	11
33	Paclitaxel-Induced Ultrasmall Gallic Acid-Fe@BSA Self-Assembly with Enhanced MRI Performance and Tumor Accumulation for Cancer Theranostics. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 28483-28493.	4.0	46
34	Smart nanoconstructs for theranostics in cancer and cardiovascular diseases. , 2018, , 297-321.		1
35	Impact of Genomics on Personalization of Breast Cancer Care. , 2018, , 331-372.		2
36	Recent advances in "smart" delivery systems for extended drug release in cancer therapy. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 4727-4745.	3.3	179
37	A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 717.	1.6	3

#	ARTICLE	IF	CITATIONS
38	Keratin nanoparticles co-delivering Docetaxel and Chlorin e6 promote synergic interaction between chemo- and photo-dynamic therapies. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2019, 199, 111598.	1.7	27
39	Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article. <i>Journal of Controlled Release</i> , 2019, 311-312, 125-137.	4.8	64
40	Paclitaxel-loaded sodium deoxycholate-stabilized zein nanoparticles: characterization and in vitro cytotoxicity. <i>Heliyon</i> , 2019, 5, e02422.	1.4	51
41	Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer. <i>Pharmaceutics</i> , 2019, 11, 31.	2.0	39
42	New designs in early clinical drug development. <i>Annals of Oncology</i> , 2019, 30, 1460-1465.	0.6	14
43	Leveraging Surface Plasmon Resonance to Dissect the Interfacial Properties of Nanoparticles: Implications for Tissue Binding and Tumor Penetration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 20, 102024.	1.7	12
44	Adding Nanotechnology to the Metastasis Treatment Arsenal. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 403-418.	4.0	32
45	Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. <i>Molecular Pharmaceutics</i> , 2019, 16, 2385-2393.	2.3	7
46	Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 16-23.	2.0	18
47	Drug Carrier-Oriented Polygeline for Preparing Novel Polygeline-Bound Paclitaxel Nanoparticles. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2012-2021.	1.6	2
48	Nanomedicines Lost in Translation. <i>ACS Nano</i> , 2019, 13, 13620-13626.	7.3	50
49	Paclitaxel formulation with stable sustained-release behavior and its biological safety evaluation. <i>Science China Technological Sciences</i> , 2019, 62, 1151-1159.	2.0	7
50	Delivery of Cancer Nanotherapeutics. <i>Bioanalysis</i> , 2019, , 163-205.	0.1	2
51	Drug-Loaded Biocompatible Nanocarriers Embedded in Poloxamer 407 Hydrogels as Therapeutic Formulations. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 7.	0.7	47
52	Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment. <i>Drug Delivery and Translational Research</i> , 2020, 10, 413-424.	3.0	31
53	Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2020, 17, 98-108.	2.3	14
54	Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy. <i>Molecules</i> , 2020, 25, 4176.	1.7	45
55	Self-Assembled Disulfide Bond Bearing Paclitaxel-Camptothecin Prodrug Nanoparticle for Lung Cancer Therapy. <i>Pharmaceutics</i> , 2020, 12, 1169.	2.0	16

#	ARTICLE	IF	CITATIONS
56	miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 624-635.	0.7	7
57	Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. <i>BMC Cancer</i> , 2020, 20, 698.	1.1	11
58	EBV-associated miR-BART12 accelerates migration and invasion in EBV-associated cancer cells by targeting tubulin polymerization-promoting protein 1. <i>FASEB Journal</i> , 2020, 34, 16205-16223.	0.2	19
59	Self-assembled non-covalent protein-drug nanoparticles: an emerging delivery platform for anti-cancer drugs. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1437-1458.	2.4	28
60	Albumin-based lipoprotein nanoparticles for improved delivery and anticancer activity of curcumin for cancer treatment. <i>Nanomedicine</i> , 2020, 15, 2851-2869.	1.7	21
61	Drug Delivery Systems of Natural Products in Oncology. <i>Molecules</i> , 2020, 25, 4560.	1.7	48
62	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 3543.	1.0	28
63	A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. <i>Biomaterials</i> , 2020, 255, 120151.	5.7	27
64	Triple-negative breast cancer molecular subtyping and treatment progress. <i>Breast Cancer Research</i> , 2020, 22, 61.	2.2	1,022
65	Introduction to Active, Smart, and Intelligent Nanomaterials for Biomedical Application. , 2020, , 1-16.		3
66	Echogenic exosomes as ultrasound contrast agents. <i>Nanoscale Advances</i> , 2020, 2, 3411-3422.	2.2	11
67	Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. <i>Science Advances</i> , 2020, 6, eaax3931.	4.7	50
68	Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 115-130.	0.8	2
69	Serum protein-based nanoparticles for cancer diagnosis and treatment. <i>Journal of Controlled Release</i> , 2021, 329, 997-1022.	4.8	89
70	Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells. <i>International Journal of Pharmaceutics</i> , 2021, 593, 120139.	2.6	20
71	pH-sensitive multi-drug liposomes targeting folate receptor $\hat{1}^2$ for efficient treatment of non-small cell lung cancer. <i>Journal of Controlled Release</i> , 2021, 330, 1-14.	4.8	53
72	PGMD/curcumin nanoparticles for the treatment of breast cancer. <i>Scientific Reports</i> , 2021, 11, 3824.	1.6	54
73	Fluoroscopy-Guided Salvage Photodynamic Therapy Combined with Nanoparticle Albumin-Bound Paclitaxel for Locally Advanced Esophageal Cancer After Chemoradiotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 410-416.	0.7	6

#	ARTICLE	IF	CITATIONS
74	Identification of In Vivo Metabolites of a Potential Anti-tumor Drug Candidate AMAC, in Rat Plasma, Urine and Feces Samples Using UHPLC/QTOF /MS/MS. <i>Current Pharmaceutical Analysis</i> , 2021, 17, 484-494.	0.3	0
75	Development of a Lyophilization Process for Long-Term Storage of Albumin-Based Perfluorodecalin-Filled Artificial Oxygen Carriers. <i>Pharmaceutics</i> , 2021, 13, 584.	2.0	5
76	Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4673.	1.8	69
77	Evaluation of the efficacy and safety of a new formulationâ€œlipid emulsionâ€œbased PTX injection: Pharmacokinetics, tissue distributions and anticancer effect on human gastric cancer cells in vitro. <i>Biomedical Chromatography</i> , 2021, 35, e5107.	0.8	2
78	Targeted dual inhibition of câ€œMet/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4950-4961.	1.6	8
79	Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes. <i>Experimental Biology and Medicine</i> , 2021, 246, 2358-2371.	1.1	20
80	Emerging nanotaxanes for cancer therapy. <i>Biomaterials</i> , 2021, 272, 120790.	5.7	25
81	Paclitaxel-Loaded Folate-Targeted Albumin-Alginate Nanoparticles Crosslinked with Ethylenediamine. Synthesis and In Vitro Characterization. <i>Polymers</i> , 2021, 13, 2083.	2.0	7
82	Paclitaxel-loaded and folic acid-modified PLGA nanomedicine with glutathione response for the treatment of lung cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 1027-1036.	0.9	12
83	Drug-Induced Peripheral Neuropathy: Diagnosis and Management. <i>Current Cancer Drug Targets</i> , 2021, 21, .	0.8	3
84	SPIOs and magnetic hybrid materials: Synthesis, toxicology and biomedical applications. <i>ChemistrySelect</i> , 2023, 8, 1435-1464.	0.7	5
85	Cancer immunotherapy from biology to nanomedicine. <i>Journal of Controlled Release</i> , 2021, 336, 410-432.	4.8	12
86	Nanocarriers as a Tool for the Treatment of Colorectal Cancer. <i>Pharmaceutics</i> , 2021, 13, 1321.	2.0	13
87	Novel pegylated liposomal formulation of docetaxel with 3-n-pentadecylphenol derivative for cancer therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105838.	1.9	11
88	A Mannosylated, PEGylated Albumin as a Drug Delivery System for the Treatment of Cancer Stroma Cells. <i>Advanced Functional Materials</i> , 2021, 31, 2104136.	7.8	11
89	Farnesylthiosalicylic Acid-Loaded Albumin Nanoparticle Alleviates Renal Fibrosis by Inhibiting Ras/Raf1/p38 Signaling Pathway. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 6441-6453.	3.3	5
90	The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy. <i>International Journal of Biological Macromolecules</i> , 2021, 187, 24-34.	3.6	46
91	Ultrasound-mediated microbubbles cavitation enhanced chemotherapy of advanced prostate cancer by increasing the permeability of blood-prostate barrier. <i>Translational Oncology</i> , 2021, 14, 101177.	1.7	17

#	ARTICLE	IF	CITATIONS
92	Onkologika. , 2016, , 583-619.		1
93	Onkologika. , 2017, , 597-639.		1
94	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 5274-5286.	0.8	24
95	Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2020, 15, 2-13.	0.8	12
96	Gold nanoparticle-mediated delivery of paclitaxel and nucleic acids for cancer therapy (Review). <i>Molecular Medicine Reports</i> , 2020, 22, 4475-4484.	1.1	23
97	Neferine induces apoptosis by modulating the ROS-mediated JNK pathway in esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2020, 44, 1116-1126.	1.2	21
98	Current Systemic Treatment Options for Metastatic and Unresectable Pancreatic Cancer. , 0, , .		1
99	7-Epitaxol Induces Apoptosis and Autophagy in Head and Neck Squamous Cell Carcinoma through Inhibition of the ERK Pathway. <i>Cells</i> , 2021, 10, 2633.	1.8	6
100	Onkologika. , 2018, , 645-691.		1
101	Translational Nanodiagnostics for In Vivo Cancer Detection. <i>Bioanalysis</i> , 2019, , 133-162.	0.1	1
102	Onkologika. , 2019, , 817-875.		0
103	Onkologika. , 2020, , 671-732.		2
104	Anti-proliferative effect of honokiol on SW620 cells through upregulating BMP7 expression via the TGF β 1/p53 signaling pathway. <i>Oncology Reports</i> , 2020, 44, 2093-2107.	1.2	6
105	Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy. , 2022, , 269-286.		0
106	The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2017, 76, 318-325.	0.4	0
108	Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study. <i>Nagoya Journal of Medical Science</i> , 2020, 82, 457-467.	0.6	1
109	Nanomedicine design principles: Facilitating clinical translation through problem-centered thinking. , 2021, , .		0
110	Breaking malignant nuclei as a non-mitotic mechanism of taxol-paclitaxel. , 2021, 2, 86-93.		4

#	ARTICLE	IF	CITATIONS
111	AMP-activated protein kinase re-sensitizes A549 to paclitaxel via up-regulating solute carrier organic anion transporter family member 1B3 expression. <i>Cellular Signalling</i> , 2022, 91, 110215.	1.7	5
112	Nanoemulsion Applications. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2022, , 259-276.	0.2	0
113	Clinical application of nano-targeting for enhancing chemotherapeutic efficacy and safety in cancer management. <i>Nanomedicine</i> , 2022, 17, 405-421.	1.7	11
114	Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas. <i>Frontiers in Oncology</i> , 2022, 12, 815900.	1.3	18
115	The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 147-161.	2.4	11
116	Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer. <i>BiolImpacts</i> , 2022, , .	0.7	1
118	Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. <i>Cells</i> , 2022, 11, 650.	1.8	34
119	Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinical Investigation to Clinic. <i>Cancers</i> , 2022, 14, 1198.	1.7	29
120	The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1417-1429.	0.8	3
121	Development, validation, and application of an UPLC-MS/MS method for vancomycin, norvancomycin, methotrexate, paclitaxel, and imatinib analysis in human plasma. <i>Annals of Clinical Biochemistry</i> , 2022, 59, 253-263.	0.8	6
122	Microtubule Organization Is Essential for Maintaining Cellular Morphology and Function. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	3
123	Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models. <i>Cancer Biology and Therapy</i> , 2021, 22, 619-629.	1.5	7
124	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. <i>Life</i> , 2022, 12, 48.	1.1	49
125	Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. <i>Molecular Pharmaceutics</i> , 2022, 19, 172-187.	2.3	0
130	Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity. <i>Journal of Cancer</i> , 2022, 13, 2362-2373.	1.2	5
131	Current therapeutics and treatment options in TNBC. , 2022, , 61-94.		4
132	Multifunctional Gold Nanoparticles in Cancer Diagnosis and Treatment. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 2041-2067.	3.3	40
133	Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer. <i>Frontiers in Medicine</i> , 2022, 9, 810761.	1.2	8

#	ARTICLE	IF	CITATIONS
134	A Nutrient Enriched Copper Based Structure as a Drug Delivery Mechanism for Paclitaxel. SSRN Electronic Journal, 0, , .	0.4	0
135	Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules, 2022, 12, 784.	1.8	48
136	Nanoparticle-based medicines in clinical cancer therapy. Nano Today, 2022, 45, 101512.	6.2	59
137	A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy. Drug Design, Development and Therapy, 0, Volume 16, 2395-2406.	2.0	7
138	Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report. Frontiers in Immunology, 0, 13, .	2.2	1
139	SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression. Biomedicine and Pharmacotherapy, 2022, 153, 113519.	2.5	3
140	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics, 2022, 12, 6106-6129.	4.6	14
141	Current status of nanomedicine for breast cancer treatment. , 2022, , 65-110.		0
142	Nab-paclitaxel plus S-1 <i>versus</i> oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study). Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211180.	1.4	7
143	Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy â€” non-mitotic mechanisms of paclitaxel. Frontiers in Oncology, 0, 12, .	1.3	5
144	Hypoxia-Activated PEGylated Paclitaxel Prodrug Nanoparticles for Potentiated Chemotherapy. ACS Nano, 2022, 16, 14693-14702.	7.3	24
145	Natural products in drug discovery and development: Synthesis and medicinal perspective of leonurine. Frontiers in Chemistry, 0, 10, .	1.8	7
146	Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resistance Updates, 2022, 65, 100881.	6.5	17
147	Engineering and Validation of a Peptide-Stabilized Poly(lactic-<i>co</i>-glycolic) Acid Nanoparticle for Targeted Delivery of a Vascular Disruptive Agent in Cancer Therapy. Bioconjugate Chemistry, 2022, 33, 2348-2360.	1.8	0
148	Preclinical Evaluation of Nanoparticle Behavior in Biological Tissues. , 2022, , 131-138.		0
149	Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	4
150	May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?. International Journal of Molecular Sciences, 2023, 24, 93.	1.8	4
151	Novel Development of Nanoparticlesâ€™ A Promising Direction for Precise Tumor Management. Pharmaceutics, 2023, 15, 24.	2.0	4

#	ARTICLE	IF	CITATIONS
152	Pharmaceutical Nanotechnology. <i>Micro/Nano Technologies</i> , 2023, , 179-283.	0.1	1
153	Perspective Chapter: Appraisal of Paclitaxel (Taxol) Pros and Cons in the Management of Cancer - Prospects in Drug Repurposing. , 0, , .		1
154	Preclinical evaluation of albumin-bound docetaxel nanoparticles as potential anti-cancer products. <i>International Journal of Pharmaceutics</i> , 2023, 635, 122711.	2.6	1
155	Lipid-conjugated siRNA hitchhikes endogenous albumin for tumor immunotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 108210.	4.8	4
156	Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
157	Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3252-3276.	5.7	7
158	Nanobiotechnology-mediated radioimmunotherapy treatment for triple-negative breast cancer. , 2023, 2, .		0
159	Theranostic applications of selenium nanomedicines against lung cancer. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	10
160	Neurotoxicity induced by taxane-derived drugs: analysis of the FAERS database 2017-2021. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 715-724.	1.0	0
161	Self-assembled protein-drug nanoparticles for enhanced drug delivery and targeting cancer therapeutics. , 2023, , 341-361.		0
162	Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7515-7527.	1.2	3
163	Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy. <i>Cancer Nanotechnology</i> , 2023, 14, .	1.9	8
185	<i>Gynecologic Cancer</i> . , 2023, , 1-48.		0